Comparison of ceftibuten once daily and amoxicillin-clavulanate three times daily in the treatment of acute exacerbations of chronic bronchitis

Clinical Therapeutics

Volumn 20, Issue 1, 1998, Pages 88-100

  McAdoo, Michael A ^a,e   Rice, Kathryn ^b   Gordon, Gregory R ^c   Sahn, Steven A ^d  

^a Milan Medical Center   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL CENTER   (United States)

^c Fairless Hills Medical Center   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^e NONE   (United States)

Author keywords

Acute exacerbations of chronic bronchitis; Amoxicillin clavulanate; Ceftibuten

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CEFTIBUTEN;

ACUTE DISEASE; ADULT; AGED; ARTICLE; CHRONIC BRONCHITIS; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG CAPSULE; DRUG EFFICACY; FEMALE; GASTROINTESTINAL TOXICITY; HAEMOPHILUS INFLUENZAE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORAXELLA CATARRHALIS; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; STREPTOCOCCUS PNEUMONIAE; TABLET;

EID: 0031905999     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(98)80037-4     Document Type: Article

References (25)

1. Anthonisen NR, Manfreda J, Warren CPW, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106: 196-204.
2. Jones RN, Barry AL. Antimicrobial activity, spectrum and recommendations for disk diffusion susceptibility testing of ceftibuten (7432-S; SCH 39720), a new orally administered cephalosporin. Antimicrob Agents Chemother. 1988;32: 1576-1582.
3. Jones RN. Ceftibuten: A review of antimicrobial activity, spectrum and other microbiologic features. Pediatr Infect Dis J. 1995;14(Suppl):S77-S83.
4. Wiseman LR, Balfour JA. Ceftibuten: A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy. Drugs. 1994;47:784-808.
5. Barr WH, Affrime M, Lin C-C, Batra V. Pharmacokinetics of ceftibuten in children. Pediatr Infect Dis J. 1993;12 (Suppl):S55-S63.
6. Barr WH, Lin C-C, Radwanski E, et al. The pharmacokinetics of ceftibuten in humans. Diagn Microbiol Infect Dis. 1991; 14:93-100.
7. Krumpe PR, Colucci R, Lin C-C, et al. The penetration of ceftibuten into the respiratory tract. Presented at the 19th International Congress of Chemotherapy; July 16-21, 1995; Montreal, Quebec, Canada.
8. Andrews JM, Wise R, Baldwin DR, Honeybourne D. Concentrations of ceftibuten in plasma and the respiratory tract following a single 400 mg oral dose. Int J Antimicrob Agents. 1995;5:141-144.
9. Hayashi I, Onuma K, Hasuike M, Ishii T. Clinical examination of ceftibuten in acute bronchitis. Jpn J Antibiot. 1990;43: 761-767.
10. Watanabe A, Oizumi K, Motomiya M, et al. Therapeutic efficacy of ceftibuten in chronic respiratory tract infections. Jpn J Antibiot. 1990;43:768-778.
11. Chirurgi VA, Edelstein H, Oster SE, et al. Ceftibuten versus cefaclor for the treatment of bronchitis. J Antimicrob Chemother. 1991;28:577-580.
12. Woodcock AJ. Epidemiology of chronic airways disease. Chest. 1989;96(Suppl): 87-92.
13. Verghese A, Ismail HM. Acute exacerbations of chronic bronchitis: Preventing treatment failures and early re-infection. Postgrad Med. 1994;96:75-89.
14. Todd PA, Benfield P. Amoxicillin/clavulanic acid: An update of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1990;39:264-307.
15. Schmidt EW, Zimmermann I, Ritzerfeld W, et al. Controlled prospective study of oral amoxycillin/clavulanate versus ciprofloxacin in acute exacerbations of chronic bronchitis. J Antimicrob Chemother. 1989; 24(Suppl B):185-193.
16. Beumer HM, Sips AP. Miraxid versus Augmentin in exacerbations of chronic bronchitis. Drugs Exp Clin Res. 1984;10: 351-356.
17. McGhie D, Kerfoot P, Talbot DJ. A comparative study of Miraxid (pivmecillinam plus pivampicillin) and Augmentin (amoxycillin plus clavulanic acid) in the treatment of lower respiratory tract infections in general practice. J Int Med Res. 1986;14:254-260.
18. Ulmer WT, Zimmermann I. A controlled trial of amoxicillin with clavulanic acid (BRL 25000) against doxycycline in chronic bronchitis. J Int Med Res. 1981; 9:372-377.
19. Penn RL, Manocha KL, Burford JG, George RB. Comparison of Augmentin and cefaclor as oral therapy for lower respiratory infections in patients with chronic lung disease. Clin Res. 1983;31:849. Abstract.
20. Croydon P. A worldwide survey of clinical experience with Augmentin. J Drug Dev. 1989;2(Suppl 1):67-69.
21. Perrotta R, McCabe R, Rumans L, Nolen T. Comparison of the efficacy and safety of ceftibuten and cefaclor in the treatment of acute bacterial bronchitis. Infect Dis Clin Pract. 1994;3:270-276.
22. Lindsay G, Guest ND. Comparison of the final efficacy and safety of ceftibuten (Sch 39720) with that of Augmentin in the treatment of acute bacterial exacerbation of chronic bronchitis. Presented at the 19th International Congress on Chemotherapy: July 16-21, 1995; Montreal, Quebec, Canada.
23. Cunha BA. The importance of compliance with oral antibiotic regimens. Adv Ther. 1988;5:297-305.
24. Urquhart J. Ascertaining how much compliance is enough with outpatient antibiotic regimens. Postgrad Med J. 1992;68 (Suppl 3):S49-S59.
25. Cockburn J, Gibberd RW, Reid AL, Sanson-Fisher RW. Determinants of non-compliance with short term antibiotic regimens. BMJ. 1987;295:814-818.